简介
姜伊鸣?博士，中山大学药学院特聘副研究员。研究方向为中药药理与毒理、肝脏代谢调控的相关研究。研究成果共发表高水平论文25篇，其中一作/共同一作10篇发表在Hepatology，British Journal of Pharmacology，Toxicological Sciences，Drug Metabolism and Disposition, Toxicology Letters, Acta Pharmacologica Sinica, Chemico-Biological Interactions, European Journal of Pharmacology等重要学术刊物上。目前主持国家自然科学基金和广东省自然科学基金项目各1项，参与国家自然科学基金项目7项。申请国家发明专利8项，已获授权4项；2014年获得中山大学优秀共产党员；2018年获得中国药理学会药物代谢-刘昌孝人才奖；2019 年“药源性肝损伤与肝再生的代谢调控基础研究”获得广东省药理学科技成果一等奖（4/9）
?
教育与工作经历
2008.09-2012.06，中山大学药学院，药学专业，获学士学位
2012.09-2015.06，中山大学药学院，药学硕士专业，获硕士学位
2015.09-2018.06，中山大学药学院，药理学专业，获博士学位
2017.9-2017.12, 美国国立卫生研究院（NIH），访问学习
2018.08至今，中山大学药学院，特聘副研究员
?
学术/社会任职
广东省药理学会药物代谢委员会委员
?
科研项目
1. 国家自然科学基金青年项目，**，2021.01-2023-12，主持。
2．广东省自然科学基金面上项目，2019A，2019.10-2022.09，主持。
3. 国家自然科学基金面上项目，**，2020.01-2023.12，参与。
4. 国家自然科学基金青年项目，**，2018.01-2020.12，参与。
5. 国家自然科学基金青年项目，**，2018.01-2020.12，参与。
6. 国家自然科学基金青年项目，**，2017.01-2019.12，参与。
7. 国家自然科学基金面上项目，**，2016.01-2019.12，参与。
8. 国家自然科学基金面上项目，**，2016.01-2019.12，参与。
9. 国家自然科学基金面上项目，**，2014.01-2017.12，参与。
?
代表性论文
Yiming Jiang (姜伊鸣),?Xinpeng Yao, Shicheng Fan, Yue Gao, Huizhen Zhang, Min Huang*, Huichang Bi*. Lipidomic profiling reveals triacylglycerol accumulation in the liver during pregnane X receptor activation-induced hepatomegaly.?J Pharm Biomed Anal.?2020. DOI:?10.1016/j.jpba.2020.113851.
Yiming Jiang# (姜伊鸣), Minghua Jin#, Jingkao Chen#, Jinwu Yan, Peiqing Liu, Meicun Yao, Weibin Cai, Rongbiao Pi*.?Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects. Eur J Pharmacol. 2020 Feb 5;868:172871.
Yiming Jiang (姜伊鸣), Dechun Feng, Xiaochao Ma, Shicheng Fan, Yue Gao, Kaili?Fu, Ying Wang, Jiahong Sun, Xinpeng Yao, Conghui Liu, Huizhen Zhang,?Leqian Xu, Aiming Liu, Frank J. Gonzalez, Yingzi Yang, Bin Gao, Min Huang, Huichang Bi*. Pregnane X Receptor Regulates Liver Size and Liver Cell Fate via Yes-associated Protein Activation. Hepatology. 2019 Jan;69(1):343-358.
Hang Zeng#, Yiming Jiang#?(姜伊鸣，共同第一作者),Pan Chen, Xiaomei Fan, Dongshun Li, Aiming Liu, Xiaochao Ma, Wen Xie, Peiqing Liu, Frank J Gonzalez, Min Huang and Huichang Bi*, Schisandrol B protects against cholestatic liver injury through pregnane X receptors. Br J Pharmacol. 2017 Apr;174(8):672-688.
Huizhen Zhang#, Yiming Jiang#?(姜伊鸣，共同第一作者), Jingjing Wu, Chuanqi Zheng, Xiaorong Ran, Dongshun Li, Min Huang, Huichang Bi*.?Metabolic mapping of Schisandra sphenanthera extract and its active lignans using a metabolomic approach based on ultra high performance liquid chromatography with high-resolution mass spectrometry. J Sep Sci. 2017 Jan;40(2):574-586.
Yiming Jiang# (姜伊鸣), Ying Wang#, Huasen Tan, Tao Yu, Xiaomei Fan, Pan Chen, Hang Zeng, Min Huang*, Huichang Bi*. Schisandrol B protects against acetaminophen-induced acute hepatotoxicity in mice via activation of the NRF2/ARE signaling pathway. Acta Pharmacol Sin. 2016 Mar;37(3):382-9.
Yiming Jiang# (姜伊鸣), Xiaomei Fan#, Ying Wang , Huasen Tan, Pan Chen, Hang Zeng , Min Huang*,?Huichang Bi*. Hepato-protective effects of six schisandra lignans on acetaminophen-induced liver injury are partially associated with the inhibition of CYP-mediated bioactivation. Chem Biol Interact. 2015 25;231:83-9.
Ying Wang#, Yiming Jiang# (姜伊鸣，共同第一作者), Xiaomei Fan, Huasen Tan, Hang Zeng, Yongtao Wang, Pan Chen, Min Huang, Huichang Bi*. Hepato-protective effect of resveratrol against acetaminophen-induced liver injury is associated with inhibition of CYP-mediated bioactivation and regulation of SIRT1-p53 signaling pathways. Toxicol Lett. 2015 16;236(2):82-9.
Yiming Jiang# (姜伊鸣), Xiaomei Fan#, Ying Wang, Pan Chen, Hang Zeng,?Huasen Tan, Frank J. Gonzalez, Min Huang*?and Huichang Bi*. Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration.?Toxicol Sci. 2015 Jan;143(1):107-15.
Xiaomei Fan#, Yiming Jiang# (姜伊鸣，共同第一作者), Ying Wang, Huasen Tan, Hang Zeng, Yongtao Wang, Pan Chen,Aijuan Qu, Frank J. Gonzalez, Min Huang, and Huichang Bi*. Wuzhi tablet (Schisandra Sphenanthera extract) protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of NRF2-ARE and p53/p21 pathways.?Drug Metab Dispos. 2014 Dec;42(12):1982-90.